YMTracker DRIPCalc v2 Launch sale

NEW Our free Dividend Tracker is live — see what your stocks pay you

Add your stocks and see every dividend they pay you — dates, amounts, and reinvested shares.

TLSA | NASDAQ

$1.11 $0.16 | 16.84%

SIGNAL:

Signal available — unlock to view

|2026-09-30 |F&G 29 |RSI 58.7

Add to favoritesFavorite

Company Overview:

Market Cap: $66.01M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $0.76 - $2.33

7.9 Year TLSA Performance Metrics:

Total Return (with DRIP): -33.5% (-5.04% CAGR)

Total Return (no DRIP): -33.5% (-5.04% CAGR)

Share Price: -33.5% (-5.04% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $6,647

Total Return $ (with DRIP): -$3,353

TLSA Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

TLSA Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

TLSA Fundamentals: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:

TLSA - Revenue

TLSA Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Earnings Per Share (EPS)

TLSA EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Net Income

🔓 See the full chart40% off right now · 7-day free trial

TLSA Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - EBITDA

🔓 See the full chart40% off right now · 7-day free trial

TLSA EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Free Cash Flow

🔓 See the full chart40% off right now · 7-day free trial

TLSA Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Free Cash Flow / Share

🔓 See the full chart40% off right now · 7-day free trial

TLSA Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Operating Income

🔓 See the full chart40% off right now · 7-day free trial

TLSA Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Gross Profit

🔓 See the full chart40% off right now · 7-day free trial

TLSA Gross Profit CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Shares Outstanding

🔓 See the full chart40% off right now · 7-day free trial

TLSA Shares Outstanding CAGR:1Y: 0.00%2Y: 1.24%5Y: 0.00%10Y: 0.00%

TLSA - Share Buybacks

🔓 See the full chart40% off right now · 7-day free trial

TLSA Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Stock-Based Comp

🔓 See the full chart40% off right now · 7-day free trial

TLSA Stock-Based Comp CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Expenses

🔓 See the full chart40% off right now · 7-day free trial

TLSA Expenses CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Revenue vs Net Income

🔓 See the full chart40% off right now · 7-day free trial

TLSA - EPS vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

TLSA - EPS vs PE Ratio

🔓 See the full chart40% off right now · 7-day free trial

TLSA - FCF vs FCF / Share

🔓 See the full chart40% off right now · 7-day free trial

TLSA - FCF vs Stock Based Comp

🔓 See the full chart40% off right now · 7-day free trial

TLSA - Cash & Debt

🔓 See the full chart40% off right now · 7-day free trial

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

TLSA - REVENUE: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TLSA Actual Revenue CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - EPS: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TLSA Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - NET INCOME: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TLSA Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - EBITDA: Actual + Estimates

🔓 See the full chart40% off right now · 7-day free trial

TLSA Actual EBITDA CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

TLSA - Net Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

TLSA Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Gross Profit Margin

🔓 See the full chart40% off right now · 7-day free trial

TLSA Gross Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Price to Earnings

🔓 See the full chart40% off right now · 7-day free trial

TLSA Price to Earnings CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Price To Sales Ratio

🔓 See the full chart40% off right now · 7-day free trial

TLSA Price To Sales Ratio CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Return on Capital Employed

🔓 See the full chart40% off right now · 7-day free trial

TLSA Return on Capital Employed CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

TLSA - Return on Invested Capital

🔓 See the full chart40% off right now · 7-day free trial

TLSA Return on Invested Capital CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Projected Future Returns & Dividends for TLSA

Based on past 7.9-year performance, here are TLSA growth metrics:

Share price CAGR of -5.04%
Dividend CAGR of +0%

Using TLSA CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	TLSA (DRIP)	TLSA - No DRIP
Current Price	$1.11	$1.11
Start Shares	9,009.01	9,009.01
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	9,009.01	9,009.01
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.66	$1.11
Total Dividends	$0	$0
Final Value	$5,963	$10,000

Estimated Future Value + Dividends - TLSA

NOTE: Above numbers are our estimate based on TLSA's Dividend and Price CAGR over past 7.9 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Company Info

Tiziana Life Sciences Ltd (TLSA) had its IPO on 2018-11-20, and is traded on NASDAQ stock exchange.

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

TLSA website: https://www.tizianalifesciences.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Most Popular

PREMIUM

$288 ($24/mo) $172.80/yr ($14.40/mo)

7-day free trial

Everything in Pro
YieldMax PNL Tracker
YieldMax NAV Erosion Alerts
YM ETFs Trend Signals
9/21 EMA Trend Signals
Stocks Dashboard

Try it free for 7 days

You save $211.20 (55%)

ULTRA

$576 ($48/mo) $345.60/yr ($28.80/mo)

7-day free trial

Everything in Premium
15min & 1hr Intraday Signals
Group & weekly ETF estimates
YouTuber Mode
Trades summary + CSV export
Priority data & support

Try it free for 7 days

You save $422.40 (55%)

Loading signals…

DCF Model — TLSA

Value from:

EPS (TTM)icompany profit per share over the last 12 months

EPS Growth %ihow fast profit per share grows each of the next 5 years — prefilled with what analysts expect

EPS growth after year 5 (forever)ithe slower pace once the fast 5 years are over — only drives years 6-10 of the price path below

Exit multiple (PE in 5 yrs)iwhat buyers pay per $1 of profit in 2031 — prefilled with today’s forward PE

Desired return %/yrithe yearly return you want from buying today — the S&P has done ~14%/yr, ask for more from a single stock

FCF growth %/yr (next 5 yrs)ihow fast free cash flow grows while the company is still expanding fast

Years of fast FCF growthihow many years the fast growth lasts before the business settles down

FCF growth after year 5 (forever)ithe slow, steady pace once the company is mature — usually 2-3%, near inflation. Must stay below your target return

Risk-free rate %iwhat a 10-yr US treasury pays with zero risk — the floor any risky stock must beat

Your target return %/yrithe yearly return you want for taking this risk — rule of thumb: risk-free rate + extra for risk

FCF base ($M, TTM)ilast 12 months of free cash flow, added up from reported quarters

Include dividends in returnidividends hand you part of the return in cash, so the share price needs to climb less

Pay up to today

—

vs current price $1.11

—

Cash flow & implied price by year

FCF is negative or missing for this company (common for banks) — the model discounts EPS instead.

EPS is negative or missing for this company — Simple mode uses free cash flow per share instead.

Free cash flow today

—

grows for the next years

Then mature

—

every future dollar counted back to today

Pile of today-dollars

—

÷ shares

Implied price path

Year	FCF	Implied price

Sensitivity — fair value: growth ↓ × target return →

× Free Portfolio Tracker

Own TLSA? See every dividend it's paid you

Add your TLSA shares to a free account and every payment you've received is listed — dated, in dollars — with reinvested shares counted and monthly totals. Room for 4 more stocks.

✓Every TLSA dividend you've received, dated, with the amount
✓Reinvested (DRIP) shares counted for you
✓Monthly totals across up to 5 stocks

See my TLSA payments →

Free plan · up to 5 holdings